Patients did not receive pre-HSCT HMA therapy in the previous study and all of our studied patients received HMA therapy prior to HSCT, so more analysis may be needed to fully understand the outcomes of TP53-mutated MDS patients who receive HSCT. Here, TP53 is linked to myelodysplastic syndrome.